1
Total investments
1
Early stage
0
Mid stage
0
Late stage
4y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Angel Investor
Sep 2022
InGel Therapeutics is Harvard-spinoff, regenerative medicine biotech leveraging novel neuroprotective mechanisms to stop retinal degeneration. Our beachhead indication is Retinitis Pigmentosa, with future expansion opportunities which include Dry-AMD and Glaucoma.
Experience · 2 entries
All (2)
Investments (1)
2022
Angel Investor
Sep 2022
InGel Therapeutics is Harvard-spinoff, regenerative medicine biotech leveraging novel neuroprotective mechanisms to stop retinal degeneration. Our beachhead indication is Retinitis Pigmentosa, with future expansion opportunities which include Dry-AMD and Glaucoma.
Associate Director, Neuroimmunology, Rare Disease, and Inflammation Training
May 2022
Horizon Therapeutics is now part of Amgen. The Horizon LinkedIn page is no longer active or monitored.